- Email: [email protected]
Response to the Letter to the Editor regarding “Protective effect of resveratrol against cisplatininduced ototoxicity in HEI-OC1 auditory cells”
International Journal of Pediatric Otorhinolaryngology 79 (2015) 1173
Contents lists available at ScienceDirect
International Journal of Pediatric Otorhinolaryngology journal homepage: www.elsevier.com/locate/ijporl
Letter to the Editor Response to the Letter to the Editor regarding ‘‘Protective effect of resveratrol against cisplatininduced ototoxicity in HEI-OC1 auditory cells’’
protective effect is not superior to other well-known anti-oxidants. Nevertheless, I do not want to ignore the significant beneficial effect of Resveratrol in low doses, and we all may agree regarding the public popularity of Resveratrol from such sources as wine or berries at this time.
Dear Sir, Conflict of interest I am happy that my study and your team’s study are aligning in our understanding of the effect of Resveratrol against cisplatininduced ototoxicity. Dr. Olgun’s team pointed out that (1) Low doses of Resveratrol had an in vitro otoprotective effect against cisplatin induced ototoxicity. (2) High doses of Resveratrol worsened the hearing much more. (3) Orally administrated Resveratrol had a questionable protective effect against cisplatin ototoxicity especially in clinical situations. Points (1) and (2) align with my study data which shows that, although a low Resveratrol concentration has a protective effect against cisplatin-induced cytotoxicity, the maximal protective effect occurred at 1 mM dose of Resveratrol. Higher concentrations of Resveratrol over 2 mM did not show the same protective effect on HEI-OC1 cells, and instead rather worsened the beneficial effect at over 10 mM concentrations. Regarding point (3), my study did not mention the questionable possibility of clinical application of Resveratrol, but it included a significant amount of data for other various anti-oxidants. Based on the study data, one may conclude that low doses of Resveratrol significantly protected cells from cisplatin ototoxicity and reduced reactive oxygen species. It is also noteworthy to conclude that Resveratrol did not meet the level of effectiveness that I had expected during my study given that the
http://dx.doi.org/10.1016/j.ijporl.2015.05.004 0165-5876/ß 2015 Elsevier Ireland Ltd. All rights reserved.
None declared. Financial disclosure None declared.
Gi Jung Im* Department of Otolaryngology – Head and Neck Surgery, Korea University College of Medicine, Inchon-ro 73, Seongbuk-Gu, Seoul, South Korea *Correspondence
to: Department of Otolaryngology – Head and Neck Surgery, Korea University Anam Medical Center, Korea University College of Medicine, Inchon-ro 73, Seongbuk-Gu, 136-705 Seoul, South Korea. Tel.: +82 2 920 5486; fax: +82 2 925 5233 E-mail address: [email protected] (G.J. Im). 5 May 2015 Available online 14 May 2015
Contents lists available at ScienceDirect
International Journal of Pediatric Otorhinolaryngology journal homepage: www.elsevier.com/locate/ijporl
Letter to the Editor Response to the Letter to the Editor regarding ‘‘Protective effect of resveratrol against cisplatininduced ototoxicity in HEI-OC1 auditory cells’’
protective effect is not superior to other well-known anti-oxidants. Nevertheless, I do not want to ignore the significant beneficial effect of Resveratrol in low doses, and we all may agree regarding the public popularity of Resveratrol from such sources as wine or berries at this time.
Dear Sir, Conflict of interest I am happy that my study and your team’s study are aligning in our understanding of the effect of Resveratrol against cisplatininduced ototoxicity. Dr. Olgun’s team pointed out that (1) Low doses of Resveratrol had an in vitro otoprotective effect against cisplatin induced ototoxicity. (2) High doses of Resveratrol worsened the hearing much more. (3) Orally administrated Resveratrol had a questionable protective effect against cisplatin ototoxicity especially in clinical situations. Points (1) and (2) align with my study data which shows that, although a low Resveratrol concentration has a protective effect against cisplatin-induced cytotoxicity, the maximal protective effect occurred at 1 mM dose of Resveratrol. Higher concentrations of Resveratrol over 2 mM did not show the same protective effect on HEI-OC1 cells, and instead rather worsened the beneficial effect at over 10 mM concentrations. Regarding point (3), my study did not mention the questionable possibility of clinical application of Resveratrol, but it included a significant amount of data for other various anti-oxidants. Based on the study data, one may conclude that low doses of Resveratrol significantly protected cells from cisplatin ototoxicity and reduced reactive oxygen species. It is also noteworthy to conclude that Resveratrol did not meet the level of effectiveness that I had expected during my study given that the
http://dx.doi.org/10.1016/j.ijporl.2015.05.004 0165-5876/ß 2015 Elsevier Ireland Ltd. All rights reserved.
None declared. Financial disclosure None declared.
Gi Jung Im* Department of Otolaryngology – Head and Neck Surgery, Korea University College of Medicine, Inchon-ro 73, Seongbuk-Gu, Seoul, South Korea *Correspondence
to: Department of Otolaryngology – Head and Neck Surgery, Korea University Anam Medical Center, Korea University College of Medicine, Inchon-ro 73, Seongbuk-Gu, 136-705 Seoul, South Korea. Tel.: +82 2 920 5486; fax: +82 2 925 5233 E-mail address: [email protected] (G.J. Im). 5 May 2015 Available online 14 May 2015